Clinical Progress in Pancreatic Cancer Therapy Unveiled Next Week in London

Amtoz Shemi, Chief Executive Officer from clinical stage biopharmaceutical company, Silenseed, will join the stellar line-up at the RNA Therapeutics conference taking place on 15th & 16th February 2016 in London, UK.

Through a case study driven address, the presentation entitled: RNAi and Tumor Microenvironment, will reveal clinical findings on the effectiveness of siRNA against mutated KRAS in pancreatic cancer. Amtoz Shemi will highlight how prolonged continues release of siRNA modifies tumor microenvironment can accelerate drug distribution and discuss developments for delivery of RNAi-based drugs.

More Here:

Posted in Charitable Work.